Meeting
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
Authors
Mehmet Asim Bilen
Winship Cancer Institute of Emory University, Atlanta, GA
Mehmet Asim Bilen , Ibrahim Khilfeh , Kevin H Li , Carmine Rossi , Erik Muser , Lilian Diaz , Laura Morrison , Annalise Hilts , Patrick Lefebvre , Dominic Pilon , Daniel J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 52)
DOI
10.1200/JCO.2024.42.4_suppl.52
Abstract #
52
Poster Bd #
B9
Abstract Disclosures
Similar Posters
First Author: Elena Castro
Poster
2023 ASCO Genitourinary Cancers Symposium
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
First Author: Vincenzo Gennusa
Poster
2023 ASCO Genitourinary Cancers Symposium
Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
First Author: Mehmet Asim Bilen
Poster
2022 ASCO Annual Meeting
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao